Substitute for form 1449A/PTO	COMPLETE F KNOWN		
INFORMATION DISC. URE	Application Number	10/520, 105 2092	
O ISTAGEMENT BY APPLICANT	Filing Date	January 7, 2004	
	First Named Inventor	David B. Olsen, et al.	
(use as inany sheets as necessary)	Group Art Unit		
(use as inany sheets as necessary)	Examiner Name		
Sheet of 3	Attorney Docket Number	21194P	

			U.S. PA	TENT DOCUMENTS	
Examine Initials*	No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/MB	1	6,777,395		Bhat et al.	08/17/2004
	2	6,812,219		LaColla et al.	11/02/2004
	3	US 2003/0060400		LaColla et al.	03/27/2003
	4	US 2003/0050229		Sommadossi et al.	03/13/2003
	5	US 2004/0097461		Sommadossi et al.	05/20/2004
	6	US 2004/0072788		Bhat et al.	04/15/2004
	7	US 2004/0147464		Roberts et al.	07/29/2004
	8	US 2004/0063658		Roberts et al.	04/01/2004
/ME	3/9	US 2004/0259934		Olsen et al.	12/23/2004
	1				
	1			•	
		•			
			 		
	T				

FOREIGN PATENT DOCUMENTS						
Examiner Cite		Foreign Patent Document				Date of Publication of
Initials*	No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
/MI	₿ţo	PCT	WO02/057425		Merck & Co., Inc.	07/25/2002
	11	PCT	WO02/32920		Pharmasset Limited	04/25/2002
	12	PCT	WO03/093290		Genelabs Technologies, Inc.	11/13/2003
	13	PCT	WO02/057287		Merck & Co., Inc.	07/25/2002
	14	PCT	WO01/92282		Novirio Pharmaceuticals Limited	12/06/2001
	15	PCT	WO01/90121		Novirio Pharmaceuticals Limited	11/29/2001
	16	PCT	WO03/051899		Ribapharm Inc.	06/26/2003
	17	PCT	WO03/062255		Ribapharm Inc.	07/31/2003
	18	PCT	WO03/062256		Ribapharm Inc.	07/31/2003
/MB	19	PCT	WO2004/065398		Ribapharm Inc.	08/05/2004

/Mark Berch/ (04/24/2007) Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form 1DS Form (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449A/PTO	COMPLETE IF KNOWN		
INFORMATION DIS SURE	Application Number	10/52	
REATEMENT DV ADDI ICANT	Filing Date	January 7, 2005	
STATEMENT BY APPLICANT	First Named Inventor	David B. Olsen, et al.	
APR 0 8 7015 (Use as rigany sheets as necessary)	Group Art Unit		
B	Examiner Name		
Steet of 3	Attorney Docket Number	21 I94P	

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
					<u> </u>	
					·	
					<u> </u>	
					· · · · · · · · · · · · · · · · · · ·	
	-		1-1		 	
			+-1			
					<u> </u>	
			+			
			1 1			

			FORE	IGN PATEN	T DOCUMENTS	
Examiner	<u> </u>	Office Number Code			Date of Publication of	
Initials*	No.				Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
	2 0	PCT	WO2004/028481		Genelabs Technologies, Inc.	04/08/2004
/ME	1	PCT	WQ2004/002999		Idenix (Cayman) Limited	01/08/2004
/MB/	22	PCT	WO2004/002422		Idenix (Cayman) Limited	01/08/2004
/MB/	23	PCT	WO2004/046331		Idenix (Cayman) Limited	06/03/2004
_	24	rer	WO2003/068244		Merck & Co., Inc./ Isis Pharm	08/21/2003
	25	PCT	WO2003/105770		Merck & Co., Inc./ Isis Pharm.	12/24/2003
	26		WO2004/007512	_	Merck & Co., Inc./ Isis Pharm	01/22/2004
	27		WO2004/009020		Merck & Co., Inc./ Isls Pharm	01/29/2004
	28-		WO2004/072090		Merck & Co., Inc.	08/26/2004
	29	PCT	WO2004/000858		Merck & Co., Inc./ Isis Pharm	12/31/2003

/Mark Berch/ (04/24/2007) Examiner Signature Date Considered *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 14498/PTO	COMPLET WF KNOWN		
INFORMATION DISC SURE	Application Number	10/520	
STATEMENT BY APPLICANT	Filing Date	January 7, 2004	
	First Named Inventor	David B. Olsen, et al.	
MR 0 8 705	Group Art Unit		
(use as midny sheets as necessary)	Examiner Name		
Sheer 3 of 3	Attorney Docket Number	21194P	

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication. MB 30	tibonucleosides (2004)					
as Inhibitors of Hepatitis C Virus RNA Replication", J. Med. Chem., Vol. 47, pp. 5284-5297 (/MB/31 Anne B. Eldrup et al., "Structure-Activity Relationship of Purine Ribonucleosides for Inhibitio C Virus RNA-Dependent RNA Polymerase", J. Med. Chem., Vol. 47, pp. 2283-2295 (2004)	2004)					
C Virus RNA-Dependent RNA Polymerase", J. Med. Chem., Vol. 47, pp. 2283-2295 (2004)	on of Hepatitis					
David B. Olsen et al., "A 7-Deaza-Adenosine Analog is a Potent and Selective Inhibitor of Hellows (Properties Antimicrobial Agents and Chemother No. 10, pp. 3944-3953 (2004)	David B. Olsen et al., "A 7-Deaza-Adenosine Analog is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties", Antimicrobial Agents and Chemotherapy, Vol. 48, No. 10, pp. 3944-3953 (2004)					
/MB/ 33 Per Hoffmann et. al., "Recent Patents on Experimental Therapy for Hepatitis C Virus Infection Opin. Ther. Patents, Vol. 13(11), pp. 1707-1723, (2003)	n", Expert					
/MB/ 34 Volker Brass et al., "Recent Developments in Target Identification against Hepatitis C Virus", Ther. Targets, Vol. 8(4), pp. 295-307, (2004)	Expert Opin.					
Murai et al., "A synthesis and an x-ray analysis of 2'-C-,3'-C- and 5'-C-Methylsangivamycins", vel. 33, pages 391-484 (1992)	Heterocycles,					
Itmori et al, "A Study on conformationally restricted sangivamycins and their inhibitory abilities kinases", Nucleic Acids Symposium Sories, vol., 27, pages 109-170 (1993); Chemical Abstract Abstract No. 160364 (1993)	Itmori et al, "A Study on conformationally restricted sangivamycins and their inhibitory abilities of protein kinases", Nucleic Acids Symposium Series, vol. 27, pages 109-170 (1993); Chemical Abstracts, vol. 118, Abstract No. 160364 (1993)					

Examiner Signature	/Mark Berch/ (04/24/2007)	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003